These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29692729)

  • 1. Pridopidine Reverses Phencyclidine-Induced Memory Impairment.
    Sahlholm K; Valle-León M; Fernández-Dueñas V; Ciruela F
    Front Pharmacol; 2018; 9():338. PubMed ID: 29692729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Dopamine Stabilizer, Pridopidine, on Basal and Phencyclidine-Induced Locomotion: Role of Dopamine D2 and Sigma-1 Receptors.
    Sahlholm K; Valle-Leon M; Taura J; Fernandez-Duenas V; Ciruela F
    CNS Neurol Disord Drug Targets; 2018; 17(7):522-527. PubMed ID: 29952269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses.
    Sahlholm K; Sijbesma JW; Maas B; Kwizera C; Marcellino D; Ramakrishnan NK; Dierckx RA; Elsinga PH; van Waarde A
    Psychopharmacology (Berl); 2015 Sep; 232(18):3443-53. PubMed ID: 26159455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
    Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
    Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pridopidine in the treatment of Huntington's disease.
    Jabłońska M; Grzelakowska K; Wiśniewski B; Mazur E; Leis K; Gałązka P
    Rev Neurosci; 2020 May; 31(4):441-451. PubMed ID: 32083454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial.
    de Yebenes JG; Landwehrmeyer B; Squitieri F; Reilmann R; Rosser A; Barker RA; Saft C; Magnet MK; Sword A; Rembratt A; Tedroff J;
    Lancet Neurol; 2011 Dec; 10(12):1049-57. PubMed ID: 22071279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.
    Squitieri F; Di Pardo A; Favellato M; Amico E; Maglione V; Frati L
    J Cell Mol Med; 2015 Nov; 19(11):2540-8. PubMed ID: 26094900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-administration of the Dopaminergic Stabilizer Pridopidine and Tetrabenazine in Rats.
    Waters S; Ponten H; Klamer D; Waters N
    J Huntingtons Dis; 2014; 3(3):285-98. PubMed ID: 25300332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
    Johnston TH; Geva M; Steiner L; Orbach A; Papapetropoulos S; Savola JM; Reynolds IJ; Ravenscroft P; Hill M; Fox SH; Brotchie JM; Laufer R; Hayden MR
    Mov Disord; 2019 May; 34(5):708-716. PubMed ID: 30575996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse.
    Kusko R; Dreymann J; Ross J; Cha Y; Escalante-Chong R; Garcia-Miralles M; Tan LJ; Burczynski ME; Zeskind B; Laifenfeld D; Pouladi M; Geva M; Grossman I; Hayden MR
    Mol Neurodegener; 2018 May; 13(1):25. PubMed ID: 29783994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington's Disease.
    Waters S; Tedroff J; Ponten H; Klamer D; Sonesson C; Waters N
    J Huntingtons Dis; 2018; 7(1):1-16. PubMed ID: 29480206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease.
    Huntington Study Group HART Investigators
    Mov Disord; 2013 Sep; 28(10):1407-15. PubMed ID: 23450660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pridopidine for the Improvement of Motor Function in Patients With Huntington's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chen S; Liang T; Xue T; Xue S; Xue Q
    Front Neurol; 2021; 12():658123. PubMed ID: 34054700
    [No Abstract]   [Full Text] [Related]  

  • 14. Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: role of sigma-1 receptors.
    Kunitachi S; Fujita Y; Ishima T; Kohno M; Horio M; Tanibuchi Y; Shirayama Y; Iyo M; Hashimoto K
    Brain Res; 2009 Jul; 1279():189-96. PubMed ID: 19433073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pridopidine for the treatment of Huntington's disease.
    Shannon KM
    Expert Opin Investig Drugs; 2016; 25(4):485-92. PubMed ID: 26881734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of mild and moderate renal impairment on the pharmacokinetics of pridopidine, a new drug for Huntington's disease.
    Rabinovich-Guilatt L; Siegler KE; Schultz A; Halabi A; Rembratt A; Spiegelstein O
    Br J Clin Pharmacol; 2016 Feb; 81(2):246-55. PubMed ID: 26407011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo pharmacology of the dopaminergic stabilizer pridopidine.
    Ponten H; Kullingsjö J; Lagerkvist S; Martin P; Pettersson F; Sonesson C; Waters S; Waters N
    Eur J Pharmacol; 2010 Oct; 644(1-3):88-95. PubMed ID: 20667452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Efficacy and Safety of Pridopidine on Treatment of Patients with Huntington's Disease: A Systematic Review and Meta-Analysis.
    Asla MM; Nawar AA; Abdelsalam A; Elsayed E; Rizk MA; Hussein MA; Kamel WA
    Mov Disord Clin Pract; 2022 Jan; 9(1):20-30. PubMed ID: 35005061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined serotonin (5-HT)1A agonism, 5-HT(2A) and dopamine D₂ receptor antagonism reproduces atypical antipsychotic drug effects on phencyclidine-impaired novel object recognition in rats.
    Oyamada Y; Horiguchi M; Rajagopal L; Miyauchi M; Meltzer HY
    Behav Brain Res; 2015 May; 285():165-75. PubMed ID: 25448429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
    Squitieri F; de Yebenes JG
    Drug Des Devel Ther; 2015; 9():5827-33. PubMed ID: 26604684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.